Please enable JS

YOU ARE

A SPONSOR / CRO

Success is when the time to access an innovative treatment is reduced.

Get more informations

Optimize patient recruitment for your clinical trials

By providing CT-SCOUT™ to your clinical sites you will both facilitate their contribution to your studies and get a better overview of the site recruitment activities for your studies. You can also further enlarge your patient reach by providing ToTem4me to referral sites, with no need to train them on your studies.

THE PATIENT JOURNEY

Telemedicine Technologies favors direct contact with patients (with the medical team via ct-scout) and (with an expert clinical trial coordinator via ToTem4me) to involve them wherever they are and empower them to make the decision to participate in a clinical trial.

Through a questionnaire based on a powerful and reliable algorithm, you can pre-select qualified patients for your trial.

A coordinator is made available to the patient following registration on ToTem4me to follow up with the patient before, during and after inclusion in a clinical trial. A notification is sent to the clinical research team once a pest has been detected on CT-SCOUT™.

Get more information

Looking for innovative digital solutions to optimize patient recruitment in IBD trials

Read the post

Testimonials

« CT-SCOUT™ is important for patients because it facilitates their enrolment in clinical trials. Before CT-SCOUT™ we missed out on a lot of patients and now we have dramatically increased accrual in our studies. We communicate on it and this has clearly increased our visibility at national and international levels » ECCO Congress Prof Laurent Peyrin-Biroulet,

Prof Laurent Peyrin-Biroulet
President, GETAID and ECCO

« CT-SCOUT™ represents a true added value to clinical research. It takes only few minutes to operate and study information is updated very quickly »

Prof Stéphane Nancey
Hepato-gastroenterology department,
Lyon-Sud University Hospital

« CT-SCOUT™ is important for patients because it facilitates their enrolment in clinical trials. Before CT-SCOUT™ we missed out on a lot of patients and now we have dramatically increased accrual in our studies. We communicate on it and this has clearly increased our visibility at national and international levels » ECCO Congress Prof Laurent Peyrin-Biroulet,

Prof Laurent Peyrin-Biroulet
President, GETAID and ECCO

LATEST NEWSOUR NEWS >

telemedecine technologies news

Telemedicine Technologies will be at Swiss Biotech Day 2025

April 29, 2025

May 5 & 6 – Basel Telemedicine Technologies is pleased to present its CleanWeb™ eClinical suite, offering flexible, regulatory-compliant solutions tailored to every phase of clinical trials. Our platform includes a wide range of modules, such as eCRF, Randomization & Trial Supply Management, ePRO, eTMF, eConsent, Data Visualization, Vigilance, Imaging, CTMS, and more. We invite […]

READ MORE
telemedecine technologies news

Drug development cost pharma $2.2B per asset in 2024 as GLP-1s drive financial return

April 29, 2025

Fierce Biotech The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. The data come from 20 pharmas that had the highest R&D budgets in 2020, as reported in Deloitte’s annual report, “Measuring the return from pharmaceutical innovation.” In 2024, the average […]

READ MORE
telemedecine technologies news

Adopting Flexible Strategies to Combat Capacity Shortages

April 29, 2025

Biopharm International In January 2025, Samsung Biologics signed a six-year, $1.4 billion contract manufacturing agreement with an as-yet undisclosed European pharmaceutical company, with production to take place at Samsung’s manufacturing site in Songdo, South Korea (1). Simultaneously, at the J.P. Morgan Healthcare Conference held in San Francisco, the company announced plans to complete construction of […]

READ MORE